Literature DB >> 9444991

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

L T Rimsky1, D C Shugars, T J Matthews.   

Abstract

A synthetic peptide, DP178, containing amino acids 127 to 162 of the human immunodeficiency virus type 1 (HIV-1) gp41 Env glycoprotein, is a potent inhibitor of virus infection and virus mediated cell-to-cell fusion (C. Wild, T. Greenwell, and T. Matthews, AIDS Res. Hum. Retroviruses 9:1051-1053, 1993). In an effort to understand the mechanism of action of this peptide, we derived resistant variants of HIV-1(IIIB) and NL4-3 by serial virus passage in the presence of increasing doses of the peptide. Sequence analysis of the resistant isolates suggested that a contiguous 3-amino-acid sequence within the amino-terminal heptad repeat motif of gp41 was associated with resistance. Site-directed mutagenesis studies confirmed this observation and indicated that changes in two of these three residues were necessary for development of the resistant phenotype. Direct binding of DP178 to recombinant protein and synthetic peptide analogs containing the wild-type and mutant heptad repeat sequences revealed a strong correlation between DP178 binding and the biological sensitivity of the corresponding virus isolates to DP178. The results are discussed from the standpoints of the mechanism of action of DP178 and recent crystallographic information for a core structure of the gp41 ectodomain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9444991      PMCID: PMC124569     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

Authors:  M Lu; S C Blacklow; P S Kim
Journal:  Nat Struct Biol       Date:  1995-12

3.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

4.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

5.  The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure.

Authors:  C Wild; T Greenwell; D Shugars; L Rimsky-Clarke; T Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  1995-03       Impact factor: 2.205

6.  Two partially overlapping antiviral peptides from the external portion of HIV type 1 glycoprotein 41, adjoining the transmembrane region, affect the glycoprotein 41 fusion domain.

Authors:  A R Neurath; K Lin; N Strick; S Jiang
Journal:  AIDS Res Hum Retroviruses       Date:  1995-02       Impact factor: 2.205

7.  The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide.

Authors:  W Weissenhorn; S A Wharton; L J Calder; P L Earl; B Moss; E Aliprandis; J J Skehel; D C Wiley
Journal:  EMBO J       Date:  1996-04-01       Impact factor: 11.598

8.  Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41.

Authors:  D C Shugars; C T Wild; T K Greenwell; T J Matthews
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

9.  A peptide from the heptad repeat of human immunodeficiency virus gp41 shows both membrane binding and coiled-coil formation.

Authors:  M Rabenstein; Y K Shin
Journal:  Biochemistry       Date:  1995-10-17       Impact factor: 3.162

10.  Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo.

Authors:  R Shibata; M D Hoggan; C Broscius; G Englund; T S Theodore; A Buckler-White; L O Arthur; Z Israel; A Schultz; H C Lane
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

View more
  164 in total

1.  Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion.

Authors:  I Muñoz-Barroso; K Salzwedel; E Hunter; R Blumenthal
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41.

Authors:  Y Weng; Z Yang; C D Weiss
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil.

Authors:  J M Matthews; T F Young; S P Tucker; J P Mackay
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Mechanisms for HIV-1 Entry: Current Strategies to Interfere with This Step.

Authors:  Georgia D. Tomaras; Michael L. Greenberg
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

5.  Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins.

Authors:  B Kobe; R J Center; B E Kemp; P Poumbourios
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

6.  Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.

Authors:  D M Eckert; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

7.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.

Authors:  Zhonghua Liu; Mei Shan; Li Li; Lu Lu; Shu Meng; Cheng Chen; Yuxian He; Shibo Jiang; Linqi Zhang
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

Review 9.  Enfuvirtide.

Authors:  Toni M Dando; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.

Authors:  Kelly Champagne; Akira Shishido; Michael J Root
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.